Updates are available Correction dated 2022-12-27

Article History

Received: 22 June 2022

Revised: 26 September 2022

Accepted: 27 September 2022

First Online: 14 November 2022

Change Date: 27 December 2022

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s00415-022-11540-x

Declarations

:

: Penny Pennington received consulting fee from EMD Serono. Dejan Jakimovski, Katherine Sacca, Marc Stecker, Carol B. Schumacher, Niels Bergsland, Alexis Lizarraga and Patricia Picco have nothing to disclose. Bianca Weinstock-Guttman received honoraria as a speaker and/or as a consultant for Biogen Idec, Sanofi &Genzyme, Genentech, Novartis, BMS, Bayer, Horizon and Janssen. Dr Weinstock-Guttman received research funds from Biogen Idec, Genentech and Novartis. Ralph HB. Benedict has received consultation or speaking fees from Bristol Myer Squibb, Biogen, Merck, EMD Serono, Roche, Verasci, Immune Therapeutics, Novartis, and Sanofi-Genzyme Channa Kolb has received speaker honoraria and consultant fees from EMD Serono, Teva Pharmaceuticals, Acorda, Novartis, Genzyme, Alexion, Genentech, Mallinckrodt and Biogen-Idec. Ralph HB Benedict received research support from Biogen, Bristol Meyers Squibb, Genzyme, Genentech, Novartis, National Institutes of Health, National Multiple Sclerosis Society, Verasci. He conslts for Immunic Therapeutics, Latin American Committee for Treatment and Research in Multiple Sclerosis, Merck, Novartis, Roche, Sanofi. He is on speaker bureau for Biogen, Bristol Meyers Squibb, EMD Serono. He received royalties from Psychological Assessment Resources. Svetlana Eckert Michael G. Dwyer has received personal compensation from Keystone Heart for consultant fees. He received financial support for research activities from Bristol Myers Squibb, Mapi Pharma, Keystone Heart, Protembis and V-WAVE Medical. Evanthia Bernitsas received research grants from Roche/Genentech, BMS, Sanofi/Genzyme, EMD Serono, Alexion, Novartis, TG Therapeutics, PCORI, Prime Education. She received consulting fee/honoraria: Biogen, Janssen and Janssen, Horizon Pharmaceuticals, Roche/Genentech, Greenwich Biosciences. Rana Zabad is a speaker for BMS and Genentech and a principal investigator on studies sponsored by Adamas Pharmaceuticals, Genentech, GW Pharma, Merck, Sanofi, and the TREAT-MS PCORI trial. She has served as a consultant or advisor to Bayer, Biogen Idec, Bristol Myers Squibb, Genentech, GW PHarma, Janssen Pharmaceuticals, Sanofi, and TG Therapeutics and was a member of the adjudication committee on the safety and efficacy of biotin in progressive MS by MedDay Pharmaceuticals. Gabriel Pardo has served on advisory boards and/or speakers’ bureau for Biogen Idec, Celgene/Bristol Myers Squibb, EMD Serono, Greenwich Biosciences, Janssen Pharmaceuticals, Novartis Pharmaceuticals, Roche/Genentech, Sanofi-Genzyme, TG Therapeutics and Viela Bio/Horizon Therapeutics; and is a member of the Scientific Advisory Board of Progentec Diagnostics Inc. Donald Negroski received fees as a speaker/consultant for: Alexion, Biogen, Bristol Myers Squibb, EMD -Serono, Gennetech, Janson, Novartis, Sanofi-Genzyme, TG Therapeutics. Martin Belkin has received honoraria for speaking and consulting from Biogen, Genentech, TG therapeutics, Alexion, Sanofi, EMD Serono and Bristol Myers Squibb. He has received research funds from Biogen, Sanofi, Genentech, EMD Serono and Abbvie. David Hojnacki received speaking and consulting fees from BMS, Biogen and Novartis. Robert Zivadinov has received personal compensation from Bristol Myers Squibb, EMD Serono, Sanofi, Keystone Heart, Protembis and Novartis for speaking and consultant fees. He received financial support for research activities from Sanofi, Novartis, Bristol Myers Squibb, Octave, Mapi Pharma, Keystone Heart, Protembis and V-WAVE Medical.